In vivo secretion of anti-CD3 x anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement

被引：0
|
作者：
Compte, Marta [1 ]
Sanz, Laura [1 ]
Alvarez-Vallina, Luis [2 ]
机构：
[1] Hosp Univ Puerta Hierro Majadahonda, Mol Immunol Unit, Madrid, Spain
[2] Aarhus Univ, Immunotherapy & Cell Engn Lab, Dept Engn, Aarhus, Denmark
来源：
MOLECULAR THERAPY | 2015年 / 23卷 / 04期
关键词：
THERAPEUTIC PROTEINS; TUMOR-GROWTH; STEM-CELLS; IMMUNOTHERAPY; INHIBITION; NEOVESSELS;
D O I：
10.1038/mt.2015.36
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：612 / 613
页数：3
相关论文
共 50 条
  • [1] Response to "In vivo secretion of anti-CD3 x anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement"
    Iwahori, Kota
    Song, Xiao-Tong
    Gottschalk, Stephen
    MOLECULAR THERAPY, 2015, 23 (04) : 613 - 613
  • [2] THE ROLE OF T-CELL ACTIVATION IN ANTI-CD3 X ANTITUMOR BISPECIFIC ANTIBODY THERAPY
    WEINER, GJ
    KOSTELNY, SA
    HILLSTROM, JR
    COLE, MS
    LINK, BK
    WANG, SL
    TSO, JY
    JOURNAL OF IMMUNOLOGY, 1994, 152 (05): : 2385 - 2392
  • [3] Novel humanized anti-Sialyl-Tn, anti-CD3 bispecific antibodies demonstrate tumor and T-cell specificity for immune activation at the tumor site
    Eavarone, David A.
    Prendergast, Jillian
    Rao, Patricia E.
    Stein, Jenna
    Behrens, Jeff
    Dransfield, Daniel T.
    CANCER RESEARCH, 2017, 77
  • [4] Bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecules for redirected T-cell cytotoxicity in hematological malignancies
    Comeau, Michael R.
    Mitchell, Danielle
    Gottschalk, Rebecca
    Misher, Lynda
    Daugherty, Mollie
    Parr, Lara
    Pavlik, Peter
    Woodruff, Brian
    Fang, Hang
    Aguilar, Megan
    Bannink, Jeannette
    Johnson, Starrla
    Li, Gary
    Miller, Robert E.
    Bader, Robert
    Zhang, Nicole
    Sewell, Toddy
    Dasovich, Maria
    Hoyos, Gabriela H.
    Blankenship, John W.
    McMahan, Catherine
    Bienvenue, David
    Gross, Jane A.
    CANCER RESEARCH, 2017, 77
  • [5] Combining anti-CD3 activated T cells armed with anti-CD3 x anti-Her2 bispecific antibody may provide an additional anti-tumor effect after stem cell transplant for breast cancer.
    Sen, M
    Wankowski, DM
    Lum, LG
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 743 - 743
  • [6] A new strategy for T cell therapy: T cells secreting TCR anti-CD3 bispecific T-cell engager
    Sun, Hanli
    Huang, Jiao
    Zhan, Kai
    Wu, Wanli
    Tang, Xianqing
    Liu, Min
    Guo, Shanshan
    Zheng, Hongjun
    Huang, Yingjie
    Zhong, Shi
    CANCER RESEARCH, 2024, 84 (06)
  • [7] Characterizing the anti-tumor response of T cell receptor gene-modified invariant natural killer T cells
    Fleming-Trujillo, Erica Linn
    Nagato, Kaoru
    Scurti, Gina
    Nishimura, Michael I.
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [8] Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets
    Yankelevich, Maxim
    Kondadasula, Sri Vidya
    Thakur, Archana
    Buck, Steven
    Cheung, Nai-Kong V.
    Lum, Lawrence G.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (07) : 1198 - 1205
  • [9] Preparation and characterization for bispecific antibodies of anti-CD3 X anti-idiotype to B cell lymphocytic leukemia
    Shen Guanxin
    Zhang Yue
    Zhu Huifen
    Yang Jing
    Wang Xiaolin
    Current Medical Science, 1999, 19 (3) : 166 - 169
  • [10] Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies
    Li Ma
    Juan Ma
    Xin Sun
    Honggang Liu
    Investigational New Drugs, 2023, 41 : 522 - 531
12345